The C1q Nephropathy Study: a CureGN and NEPTUNE Ancillary Study (H-47042)

The goal is to relate longitudinal clinical data to digital kidney pathology and genetic sequencing, for patients in the NEPTUNE and CureGN cohorts with C1q nephropathy. The Cure Glomerulopathy Network (CureGN) has enrolled and is following 2,400 adults and children with the four major glomerular diseases: IgA nephopathy (IgAN), IgA vasculitis-associated glomerulonephritis (IgAV-GN), focal segmental glomerulosclerosis (FSGS), minimal change nephrotic syndrome (MCNS), and membranous nephropathy (MN). The Nephrotic Syndrome Study Network (NEPTUNE) has enrolled 710 patients with IgAN, FSGS, and MCNS, and has taken a precision medicine approach to characterize patients at a genetic, molecular, and ultrastructural level. The goal of this ancillary study is to determine whether the subset of FSGS and MCNS patients who qualify for a biopsy diagnosis of C1q nephropathy should be treated differently than FSGS and MCNS patients who do not also have C1q nephropathy.